October 5, 2026
Abbott Laboratories, a publicly traded multinational healthcare company, has agreed to pay nearly $385 million to resolve allegations that it knowingly manufactured powder infant formula in unsanitary conditions. The settlement, announced jointly by the Department of Justice and 39 states plus the District of Columbia, is one of the largest food-safety-related False Claims Act resolutions to date.
According to the government’s complaint, Abbott knew that its Sturgis, Michigan production facility had leaks that caused runoff water to drip directly over production equipment. Rather than fixing the roof, however, Abbott deployed large “leak umbrellas” to divert water away from machinery. Yet, even with the umbrellas in place, the resulting damp environment created fertile ground for dangerous bacteria to contaminate the formula. The government alleges that Abbott leadership knew about that risk as well.
Investigators also found that Abbott continued to use broken spray dryers — the equipment that turns liquid formula into powder — after documenting cracks in the machinery that let moisture seep in. Abbott allegedly made the problem worse by increasing the number of batches run through the dryers between cleanings, a change that boosted output and cut costs but raised contamination risk.
Finally, Abbott leadership knew of the unsafe conditions and avoided testing its products for bacterial growth to avoid positive results. When internal testing identified microbial contamination, the company allegedly concealed those results from the FDA during 2019 and 2022 facility inspections.
When companies contract with state or federal payers, they typically promise to abide by laws and industry regulations attached to that funding. When a company falls short of those standards and still bills the government for payment, constitutes a false claim because taxpayers are not receiving what they bargained for.
Here, Abbott contracted with the U.S. Department of Agriculture (“USDA”) to supply baby formula to its Special Supplemental Nutrition Program for Women, Infants, and Children (“WIC”). Infant formula purchased through WIC and state Medicaid programs represents an enormous share of the market. In fact, WIC and related programs account for more than half of all infant formula sold in the United States.
Accordingly, when a manufacturer misrepresents the quality of its formula, that misrepresentation flows directly to public health programs, the taxpayers who fund them, and, most importantly, the families those programs serve. The United States alleged that Abbott knowingly fell short of USDA safety and quality standards, yet continued billing the government to profit from its allegedly faulty product. This conduct harkens back to the inception of the False Claims Act, which was enacted to prevent contractors from billing the Union Army for faulty weapons and rotten meat during the Civil War.
Under the agreement, Abbott will pay $348,700,868 to the federal government to resolve the False Claims Act allegations, plus an additional $36,298,172 to the states whose Medicaid and WIC programs paid for the affected products.
As is true of most significant False Claims Act settlements, this case began with whistleblowers.
Three whistleblowers filed lawsuits under the False Claims Act’s qui tam provisions, which allow private individuals with knowledge of fraud against the government to file suit on the government’s behalf, and to share in the government’s recovery. Here, the whistleblowers will collectively receive $69 million as their share of the federal settlement. Their insider knowledge of conditions inside the Sturgis facility, and of Abbott’s internal decisions about how to respond to known contamination risks, was almost certainly central to building the case.
Fraud against programs like Medicare and Medicaid grabs headlines and accounts for the lion’s share of dollars collected through FCA settlements, but this case is a useful reminder that False Claims Act exposure isn’t limited to billing and coding fraud. Any company that sells products or services to taxpayer-funded programs — whether supplying concrete for a public works project, or security training to the military — can face liability when it misrepresents whether those products meet the standards the government is paying for.
It’s also a reminder that whistleblowers are central to uncovering this kind of fraud. Regulators and auditors are unlikely to have insight into day-to-day manufacturing conditions, internal risk assessments, or decisions to withhold unfavorable test results. Employees on the inside are often the only ones positioned to know what’s actually happening on the plant floor, and, in cases like this one, to protect families from receiving dangerous baby formula.
Companies that contract with the government should also take notice: proactive compliance measures save money in the long run. Fixing a leaky roof is far cheaper than settling a False Claims Act suit.
Whistleblower Law Collaborative has extensive experience representing whistleblowers in False Claims Act matters. If you have information concerning potentially fraudulent practices affecting taxpayer-funded programs, please contact us for a free and confidential consultation.